Horizon extends industry-leading gene editing IP portfolio through expansion of CRISPR license rights with ERS Genomics

Cambridge, UK, and Dublin, Ireland, 05 December, 2017: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Group”), a global leader in gene editing and gene modulation technologies, and ERS Genomics Ltd., today announce the extension of their pre-existing non-exclusive, worldwide license agreement to significantly expand Horizon’s license coverage for the use of the CRISPR gene editing technology. This will enable Horizon to use CRISPR in multiple new areas across its products and services, providing access to additional revenue streams in new and existing markets, and further reinforcing Horizon’s leadership position in gene editing and cell biology.

• Breadth of research use rights now expanded to include multiple new species
• Grant of rights to have products made and sold by partners
• Grant of sub-licensed rights to one spin-out company

For more information, please visit: https://www.horizondiscovery.com/about-us/news/horizon-extends-industry-leading-gene-editing-ip-portfolio-through-expansion-of-crispr-license-rights-with-ers-genomics

More within